Enhancing the Diversity of Participants in the WISDOM Clinical Trial: Practical Challenges and Ethical Implications
增强 WISDOM 临床试验参与者的多样性:实际挑战和伦理影响
基本信息
- 批准号:10367828
- 负责人:
- 金额:$ 16.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionAnthropologyAnxietyAttentionBioethicsBreast Cancer DetectionCaringClinical ResearchClinical TrialsCollaborationsCommunitiesDataDiagnosisDiagnostic testsDiseaseEnrollmentEthical IssuesEthicsFeedbackFrequenciesFundingGenomic medicineGenomicsGeographyGoalsGoldHarm ReductionHealth BenefitHealthcareHispanicsIncidenceIndividualInterviewInvestigationLearningLiteratureMalignant NeoplasmsMammographic screeningMammographyMeasuresMethodsModalityOperative Surgical ProceduresOutcomeParticipantPatient-Focused OutcomesPoliciesPoliticsPopulationPopulation HeterogeneityPractical trialPragmatic clinical trialProcessRandomizedRecommendationRegretsResearchResearch DesignResearch PersonnelRiskRisk AssessmentSiteSociologySurveysTechnologyTestingTimeTimeLineWomanWorkbasebehavior measurementbehavioral outcomecancer health disparityclinical careclinical research siteclinical riskcohortcostethical legal social implicationethnic diversityexperiencegenomic datahigh riskimplementation barriersimprovedinnovationinsightlegal implicationmalignant breast neoplasmmolecular pathologyparent grantpersonalized approachpolicy implicationpopulation basedpopulation healthpragmatic trialprecision medicinepreventive interventionprimary endpointpsychologicpsychological outcomesracial diversityrandomized trialrecruitrisk perceptionroutine screeningscreeningsocialsocial implicationstandard of carestudy populationtrial comparinguptakevolunteerworking group
项目摘要
Title: Enhancing the Diversity of Participants in the WISDOM Clinical Trial: Practical Challenges and Ethical
Implications.
Abstract
This bioethics supplement request expands the work of our NCI-funded R01 Expanding the WISDOM Study’s
Diversity, Reach, and Generalizability. WISDOM (Women Informed to Screen Depending on Measures of Risk)
is a pragmatic trial comparing a risk-based approach to breast cancer screening—in which the frequency and
modality of screening is dependent on a personalized risk calculation—against the gold standard of annual
screening. The goal is to determine whether a personalized approach is as safe, less morbid, better accepted
by women, encourages uptake of preventive interventions, and is of higher health care value (better outcomes
at less cost psychologically, physically, and financially). The purpose of the parent grant (which sponsors the
supplement) is to increase enrollment and enhance the diversity of the WISDOM study population in order to
increase generalizability to the US population. The proposed supplement builds upon a unique interdisciplinary
partnership between the WISDOM clinical trial team and a team of ELSI investigators funded by a separate
NCI R01 to study the social and ethical implications of WISDOM, titled: Precision Genomics in the WISDOM
Pragmatic Clinical Trial: An “Embedded" ELSI Study of Risk-based Breast Cancer Screening. This project uses
empirical and normative bioethics methods to identify and analyze the ELSI (ethical, legal, and social
implications) challenges of risk-based screening. The embedded ethics project is guided by an overarching
objective: to understand the intersection of precision genomics screening with known cancer health disparities.
The proposed bioethics supplement will facilitate and expand research on the ELSI issues that arise as the
WISDOM trial continues to innovate and evolve in order to meet its recruitment and retention goals and its
commitment to enhance inclusion of diverse populations. The new aims proposed for the supplement will
expand upon this unique opportunity and will address critical emerging issues not included in our original study
design. Our Specific Aims are: (1) To expand the Ethics Working Group to include representatives from
WISDOM’s four new enhanced-diversity recruitment sites and to extend the Ethics Working Group through
2022, allowing the group to continue to offer advice to WISDOM stakeholders in real time; and (2) To elucidate
the challenges of enrolling racially and ethnically diverse participants in the WISDOM trial by interviewing study
decliners across the original clinical study sites along with newly added clinical sites selected to enhance
diversity. The proposed supplement is significant because little is known about recruitment of diverse
populations in fully online studies. WISDOM’s efforts to enhance diversity while maintaining a largely online
approach to recruitment requires study. This research with decliners will not only fill a gap in the literature but
also will be used to enhance WISDOM recruitment processes, improve participant experiences, and help
achieve recruitment goals.
标题:提高WISDOM临床试验参与者的多样性:实践挑战和伦理
影响。
摘要
这一生物伦理学补充申请扩展了我们的NCI资助的R 01扩展WISDOM研究的
多样性,范围和普遍性。WISDOM(妇女被告知根据风险措施进行筛查)
是一项务实的试验,比较了基于风险的乳腺癌筛查方法,
筛查的方式取决于个性化的风险计算,而不是每年一次的黄金标准。
筛选我们的目标是确定个性化的方法是否安全,更少的病态,更好地接受
鼓励妇女采取预防性干预措施,并具有更高的保健价值(更好的结果
在心理上、身体上和经济上花费较少)。父母补助金的目的(资助
补充)是为了增加入组人数,提高WISDOM研究人群的多样性,
提高对美国人口的普遍性。拟议的补充建立在一个独特的跨学科
WISDOM临床试验团队和ELSI研究人员团队之间的合作伙伴关系,
NCI R 01研究WISDOM的社会和伦理影响,标题为:WISDOM中的精确基因组学
实用的临床试验:基于风险的乳腺癌筛查的“嵌入式”ELSI研究。本项目采用
确定和分析ELSI(伦理的、法律的和社会的)的经验和规范生物伦理学方法
影响)的风险为基础的筛选的挑战。嵌入式道德操守项目的指导方针是
目的:了解精确基因组学筛查与已知癌症健康差异的交叉点。
拟议的生物伦理学补编将促进和扩大对环境和社会科学研究所出现的问题的研究,
WISDOM试验不断创新和发展,以满足其招聘和保留目标,
致力于加强对不同人群的包容。为补充方案提出的新目标将
扩大这一独特的机会,并将解决我们最初的研究中没有包括的关键新问题
设计我们的具体目标是:(1)扩大道德工作小组的成员,包括
WISDOM的四个新的增强多样性招聘网站,并通过以下方式扩大道德工作组
2022年,允许该小组继续向WISDOM利益相关者提供真实的建议;以及(2)阐明
通过访谈研究招募种族和民族多样性参与者参与WISDOM试验的挑战
沿着新增加的临床研究中心,
多样性拟议的补充是重要的,因为很少有人知道招聘不同的
完全在线研究中的人群。WISDOM努力增强多样性,同时保持在线
招聘方式需要研究。这项对下降者的研究不仅填补了文献中的空白,
还将用于增强WISDOM招募流程,改善参与者体验,并帮助
实现招聘目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAURA J ESSERMAN其他文献
LAURA J ESSERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAURA J ESSERMAN', 18)}}的其他基金
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
- 批准号:
10368970 - 财政年份:2020
- 资助金额:
$ 16.15万 - 项目类别:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
- 批准号:
10593908 - 财政年份:2020
- 资助金额:
$ 16.15万 - 项目类别:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
- 批准号:
9888251 - 财政年份:2020
- 资助金额:
$ 16.15万 - 项目类别:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
I-SPY2:改进 I-SPY 2 试验,纳入 MRI 引导的适应性序贯治疗,以优化乳腺癌结果
- 批准号:
9789198 - 财政年份:2017
- 资助金额:
$ 16.15万 - 项目类别:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
I-SPY2:改进 I-SPY 2 试验,纳入 MRI 引导的适应性序贯治疗,以优化乳腺癌结果
- 批准号:
10013133 - 财政年份:2017
- 资助金额:
$ 16.15万 - 项目类别:
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
I SPY 2.2 试验:演变为影像学和分子生物标志物反应指导的适应性序贯治疗以优化乳腺癌结果
- 批准号:
10628608 - 财政年份:2017
- 资助金额:
$ 16.15万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Standard Grant